Skip to main content
Contact Us
Subscribe
E-Edition
67°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
111.08
+0.31 (+0.28%)
Official Closing Price
Updated: 7:00 PM EST, Dec 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
66
67
Next >
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
Today 4:59 EST
Via
The Motley Fool
Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt
December 07, 2024
Dental supply maker Patterson Companies Inc announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value.
Via
Benzinga
Topics
Supply Chain
Exposures
Supply Chain
3 No-Brainer Growth Stocks to Buy in December
December 07, 2024
Via
The Motley Fool
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
December 07, 2024
Via
The Motley Fool
Stock Market Hits Highs On Salesforce, Tech Earnings; Bitcoin Tops $100,000, Briefly: Weekly Review
December 06, 2024
Salesforce and mostly positive tech earnings buoyed the major indexes.
Via
Investor's Business Daily
Despite its growth, NYSE:NVO remains within the realm of affordability.
December 06, 2024
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) stands out as a growth opportunity that won't break the bank.
Via
Chartmill
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
December 06, 2024
Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies.
Via
MarketBeat
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
December 05, 2024
GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024.
Via
Benzinga
2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick
December 05, 2024
Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate.
Via
MarketBeat
Topics
Government
Lawsuit
Exposures
Financial
Legal
Political
What the Options Market Tells Us About Novo Nordisk
November 29, 2024
Via
Benzinga
Is Novo Nordisk Stock a Buy?
November 29, 2024
Via
The Motley Fool
The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market
December 05, 2024
An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in obesity.
Via
Investor's Business Daily
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
December 05, 2024
Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable.
Via
The Motley Fool
Lilly Tops Nordisk In Weight Loss Battle
December 05, 2024
The two market-leading weight loss/obesity drugs (GLP-1), Zepabound (Eli Lilly) and Wegovy (Novo Nordisk), just completed a clinical side-by-side trial.
Via
Talk Markets
Topics
Stocks / Equities
Wegovy Maker Novo Nordisk To Buy Novavax's Czech Republic Manufacturing Facility For $200 Million
December 04, 2024
Novavax sells Czech manufacturing facility to Novo Nordisk for $200 million, aiming to cut costs by $80 million annually and support its growth strategy.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
December 04, 2024
Via
Benzinga
Stock Of The Day: Where Will The Eli Lilly Rally End?
December 04, 2024
Shares of Eli Lilly (LLY) are approaching a price level that had previously been a peak. There is a good chance they hit resistance at it.
Via
Benzinga
Eli Lilly's Zepbound Vs. Novo Nordisk's Wegovy - Which Shows Greater Weight Loss?
December 04, 2024
Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable safety profile.
Via
Benzinga
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy In Head-To-Head Weight-Loss Trial
December 04, 2024
Lilly touted findings from the first head-to-head clinical trial.
Via
Investor's Business Daily
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
December 04, 2024
Via
The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
December 03, 2024
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market.
Via
Benzinga
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
December 03, 2024
Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the booming weight loss market with tactical trading opportunities.
Via
Benzinga
Topics
ETFs
Technical Monday: Novo Nordisk, A Love Story
December 02, 2024
The stock has found some buyers as we begin December. Plus, holding the 23-month MA means that the company’s stock is still in a positive 2-year business cycle expansion.
Via
Talk Markets
Topics
Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
December 02, 2024
Via
Benzinga
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
December 02, 2024
Pharma companies lobby for changes to Medicare drug price rules, targeting a four-year delay for pills' eligibility. Critics warn it may hinder patient access and innovation.
Via
Benzinga
Weight Loss Drugs Like Wegovy, Zepbound Linked To Reduced Alcohol Use: Study
December 02, 2024
A study finds that anti-obesity medications may help reduce alcohol consumption, with nearly half of participants in weight loss programs reporting decreased use.
Via
Benzinga
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy?
November 30, 2024
Via
The Motley Fool
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
November 29, 2024
Analysts are concerned about Viking's ability to compete in the lucrative obesity drug market, dominated by Eli Lilly and Novo Nordisk.
Via
Benzinga
The Ultimate Pharmaceutical Stock to Buy With $1,000 Right Now
November 27, 2024
Via
The Motley Fool
Vanity Trades Moving And The Weekly Moving Average Trigger
November 26, 2024
A discussion about exponential moving average and price for our
Via
Talk Markets
Topics
Stocks / Equities
< Previous
1
2
3
4
5
6
7
8
9
...
66
67
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.